Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Prostatic Neoplasms 11Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Follicular 8Leukemia 8Lymphoma, Non-Hodgkin 7Burkitt Lymphoma 5Hodgkin Disease 4Neoplasm Metastasis 3Lymphoma, Large-Cell, Immunoblastic 3Leukemia, Biphenotypic, Acute 3Dendritic Cell Sarcoma, Interdigitating 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Urogenital Neoplasms 1Thymoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Myasthenia Gravis 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1

Interventions

pegaspargase 3merphos 3dexamethasone acetate 3dexamethasone 21-phosphate 3azathiopurine 3auricularum 3Vincristine 3Thioguanine 3Methotrexate 3Mercaptopurine 3Leucovorin 3Doxorubicin 3Dexamethasone 3Cytarabine 3Cyclophosphamide 3Calcium Dobesilate 3prednylidene 2deltacortene 2blinatumomab 2Radiotherapy 2Radiation 2Prednisone 2Prednisolone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Methylprednisolone 2Asparaginase 2calaspargase pegol 1asparaginase erwinia chrysanthemi recombinant 1Specimen Handling 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Prednisolone × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡